Indegene LimitedInformation TechnologyINDGN
Q1 FY27 concall · earnings callIndegene Limited
The company is positioned as a strategic operating partner for the global life sciences industry, focusing on embedding AI to transform client operations and drive growth, while aiming to recover margins after a year of heavy investment.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue | ₹3,510.5 Cr | 23.6% | |
| EBITDA | ₹624.7 Cr | 11.1% | |
| Profit After Tax | ₹401.1 Cr | — | |
| Operating Cash Flow | ₹650 Cr | — | |
| Revenue per Employee | USD 75,000 | — | |
| Enterprise Commercial Solutions Revenue | ₹2,461 Cr | 27.0% | |
| Enterprise Medical Solutions Revenue | ₹930 Cr | 16.0% |
Financials
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹720.40 Cr— YoY+4.9% QoQ | ₹109.70 Cr— YoY+19.6% QoQ | ₹4.59— YoY+19.5% QoQ |
| Q2 FY25 | ₹686.80 Cr— YoY+1.5% QoQ | ₹91.70 Cr— YoY+4.6% QoQ | ₹3.84— YoY+1.3% QoQ |
| Q1 FY25 | ₹676.50 Cr— YoY+0.5% QoQ | ₹87.70 Cr— YoY-7.5% QoQ | ₹3.79— YoY-11.2% QoQ |
| Q4 FY24 | ₹673.00 Cr— YoY— QoQ | ₹94.80 Cr— YoY— QoQ | ₹4.27— YoY— QoQ |
TL;DR
- Revenue grew 23.6% to INR 35,105 million (USD 396.9 million), crossing INR 3,500 crores annually.
- EBITDA grew 11.1% to INR 6,247 million; PAT was INR 4,011 million with margins impacted by AI and acquisition investments.
- Active clients grew from 73 to 91; clients above USD 1 million in revenue grew from 41 to 53.
- Completed three acquisitions, including BioPharm for ~INR 882 crores.
- Focus for next 24 months includes deepening client pyramid, investing in AI, and margin expansion.
- Management expects EBITDA margins to return to the 19% to 20% band by Q4 FY27.
Said on the call
“We are a prototype of a new category, a partner that takes accountability for regulated workflows and business outcomes they produce.”
From the Q&A
| Topic | What management said |
|---|---|
| 24-Month Priorities and Margins | Priorities are deepening the client pyramid (aiming for a USD 50 million client), investing in AI, and improving margins. Margins dipped due to heavy investments; focus is on translating investments into margin expansion, with EBITDA margins expected to return to 19%-20% by Q4 FY27. |
| Aspirations for 2030 | Aim to be a category-defining AI-native operating partner for life sciences. Key indicators to track: revenue growing faster than headcount, broadening client base (more $1M, $10M, $25M relationships, first $50M+ account), EBITDA margins recovering to 19%-20%, and strong cash generation. |
| Acquisition Strategy and Financial Targets | The board and management have a disciplined capital allocation approach with governance. They factor in EBITDA, ROCE, and ROE for acquisitions. They are willing to take short-term margin hits for long-term value. The cash balance (INR 1,700+ crores) will be used for growth and selective acquisitions in the commercialization lifecycle. |
| Margin Recovery Steps | Lower EBITDA margins were due to growth investments (normalizing by year-end, ~150 bps positive impact) and a large outcome-based deal (signed Dec '25, 1%-1.5% favorable impact starting Q3). PAT margins are impacted by higher amortization, which will decline by ~INR 50 crores per quarter starting Q3. |
| AI's Role and Talent | AI is a tailwind, helping move upstream and access larger client budgets, not just acquire new clients. The company has a skilled AI team built over a decade and will continue to add specialized talent as needed. |
| BioPharm Acquisition Details | Acquisition cost was USD 104 million (INR ~882 crores). USD 65 million paid at closing, with a pending earn-out of USD 19 million due in 2027. BioPharm contributed USD 21.5 million to FY26 revenue. Organic growth excluding BioPharm was in the mid-teens. |
| Geographic and Customer Concentration | ~74%-75% revenue from North America, ~22% from Europe, ~2.5% from Rest of World. Top five customers constitute ~30% of revenue; the largest customer is under 10% and is a top 10 global pharma innovator company. |
| Capex | Company operates an asset-light model. FY27 capex expected to be ~1% of revenue, mainly for compute and server devices. |
Guidance
- EBITDA margins expected to return to the 19% to 20% band by Q4 FY27.
- Growth investments (150 bps impact) to normalize by end of FY27.
- Amortization charge to decline by about INR 50 crores every quarter starting Q3.
- Capex for FY27 expected to be around 1% of revenue.
- Dividend policy: to consider increases based on strong cash flow generation.
Source
Summary written from the transcript filed by Indegene Limited for the call held on 13 Aug 2026; published 18 Aug 2026, 20:17 IST.
More Q1 FY27 concalls ·How verification works ·Report an error